Skip to content

US · ITGR · MEDICAL - DEVICES

Integer Holdings Corporation (ITGR) intrinsic value and stock valuation

$126.97as of 2026-11-21 · Mkt cap 4.24B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Integer Holdings Corporation DCF and intrinsic value

InvestorsCraft values ITGR with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from ITGR’s statements →

Integer Holdings Corporation Graham Number

Graham Number: $57.85d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Plano, TX 75024 integer.net

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.85B+11.5% 5y CAGRd
20112025
Net income
$102.8M+5.9% 5y CAGRd
20112025
Free cash flow
$105.1M-4.1% 5y CAGRd
20112025
Total equity
$1.75B+6.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.85B$1.72B$1.56B$1.33B$1.22B
Operating income$209.3M$208.2M$163.3M$112.7M$135.7M
Net income$102.8M$119.9M$90.7M$66.4M$96.8M
EPSd$2.89M$3.36M$2.69M$1.99M$2.91M
Operating cash flow$196.2M$205.2M$180.2M$116.4M$156.7M
Capital expenditure-$-91.03M-$-105.36M-$-119.94M-$-74.73M-$-53.46M
Free cash flow$105.1M$99.9M$60.3M$41.7M$103.2M
Total assets$3.41B$3.08B$2.94B$2.79B$2.58B
Total debt$1.4B$1.1B$1.05B$1.01B$905.8M
Net debt$1.38B$1.06B$1.03B$984.5M$887.9M
Total equity$1.75B$1.62B$1.52B$1.42B$1.35B
Cash and short-term investments$17.2M$46.5M$23.7M$24.3M$17.9M
Income statement
20252024202320222021
Revenue$1.85B$1.72B$1.56B$1.33B$1.22B
Cost of revenue$1.42B$1.26B$1.14B$984.6M$884.1M
Gross profit$425.8M$461.2M$411.5M$346.7M$337M
Research and development expenses$46.4M$53.4M$62M$59.8M$52M
Selling, general and administrative expenses$162.6M$184.3M$171.5M$157.4M$141.7M
Other expenses$7.6M$15.2M$14.8M$16.9M$7.58M
Operating expenses$216.5M$253M$248.2M$234M$201.3M
Cost and expenses$1.64B$1.51B$1.39B$1.22B$1.09B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$42.3M$56.4M$53.4M$37.3M$31.6M
Depreciation and amortization$126M$109.7M$97M$90.9M$81.6M
Ebitda$293.7M$332.9M$275.7M$221.8M$224.7M
Operating income$209.3M$208.2M$163.3M$112.7M$135.7M
Total other income/expenses, net-$-83.87M-$-60.67M-$-57.94M-$-44M-$-34.65M
Income before tax$125.4M$147.6M$105.4M$68.7M$101.1M
Income tax expense$22.6M$26.5M$16.2M$8.93M$8.04M
Net income$102.8M$119.9M$90.7M$66.4M$96.8M
Weighted average shares outstanding$34.7M$33.6M$33.3M$33.1M$33M
Weighted average diluted shares outstanding$35.6M$35.7M$33.8M$33.4M$33.3M
Balance sheet
20252024202320222021
Cash and short-term investments$17.2M$46.5M$23.7M$24.3M$17.9M
Net receivables$346.1M$349M$317.2M$298.3M$251.8M
Inventory$253.7M$247.1M$229.1M$208.8M$155.7M
Total current assets$770.1M$671.1M$617.7M$558.3M$453M
Property, plant and equipment, net$672M$579.6M$501.4M$400.9M$347.2M
Goodwill and intangible assets$1.94B$1.8B$1.79B$1.8B$1.73B
Long-term investments$7.96M$7.42M$11.8M$13.9M$21.8M
Total non-current assets$2.64B$2.41B$2.32B$2.24B$2.13B
Total assets$3.41B$3.08B$2.94B$2.79B$2.58B
Accounts payable$113.1M$101.5M$118.3M$110.8M$76.9M
Short-term debt$22.1M$25.7M$10.9M$29.6M$25.1M
Deferred revenue$5.21M$4.44M$6.14M$5.62M$3.78M
Total current liabilities$232M$227.2M$221M$223.8M$159.6M
Long-term debt$1.38B$1.08B$1.04B$979.1M$880.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.43B$1.23B$1.2B$1.15B$1.07B
Capital lease obligations$110.5M$101.5M$82.4M$72.1M$67.2M
Total liabilities$1.66B$1.46B$1.42B$1.38B$1.23B
Common stock$40K$30K$30K$30K$30K
Retained earnings$994.1M$891.3M$771.4M$680.7M$614.3M
Accumulated other comprehensive income (loss)$58.2M-$-14.04M$20.2M$5.33M$27.2M
Total equity$1.75B$1.62B$1.52B$1.42B$1.35B
Total investments$7.96M$7.42M$11.8M$13.9M$21.8M
Total debt$1.4B$1.1B$1.05B$1.01B$905.8M
Net debt$1.38B$1.06B$1.03B$984.5M$887.9M
Cash flow statement
20252024202320222021
Net income$102.8M$119.9M$90.7M$66.4M$96.8M
Depreciation and amortization$130.7M$111M$98.8M$92M$81.4M
Stock-based compensation$23.2M$24.8M$23.3M$21M$16.2M
Change in working capital-$-120.42M-$-54.62M-$-52.3M-$-75.85M-$-47.74M
Accounts receivable-$-89.66M-$-24.98M-$-21.08M-$-41.38M-$-17.54M
Inventory-$-2.58M-$-18.08M-$-30.18M-$-56.72M$4.7M
Accounts payable-$-570K-$-16.62M-$-520K$26M$19.5M
Net cash provided by operating activities$196.2M$205.2M$180.2M$116.4M$156.7M
Investments in property, plant and equipment-$-91.03M-$-105.36M-$-119.94M-$-74.73M-$-53.46M
Acquisitions, net-$-178.87M-$-138.54M-$-43.6M-$-126.64M-$-217.98M
Net cash used for investing activities-$-270.73M-$-195.41M-$-163.37M-$-200.42M-$-271M
Common stock issued$3.64M$740K$0.00$0.00$0.00
Common stock repurchased-$-50.01M$0.00-$-3.1M-$-2.93M-$-4.59M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$43.6M$13.3M-$-18.01M$92.5M$82M
Net change in cash-$-29.38M$22.9M-$-600K$6.39M-$-31.32M
Cash at end of period$17.2M$46.5M$23.7M$24.3M$17.9M
Operating cash flow$196.2M$205.2M$180.2M$116.4M$156.7M
Capital expenditure-$-91.03M-$-105.36M-$-119.94M-$-74.73M-$-53.46M
Free cash flow$105.1M$99.9M$60.3M$41.7M$103.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Integer Holdings Corporation

        Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.

        CEO
        Payman Khales
        Employees
        11K
        Beta
        0.64

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Integer Holdings Corporation (ITGR)?

        Integer Holdings Corporation (ITGR) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ITGR undervalued?

        ITGR trades at a price of $126.97 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.